Multiple sclerosis（MS） is characterized by chronic inflammation in conjunction with neurodegeneration within the central nervous system. Most individuals with MS begin with a relapsing remitting course that later tr...Multiple sclerosis（MS） is characterized by chronic inflammation in conjunction with neurodegeneration within the central nervous system. Most individuals with MS begin with a relapsing remitting course that later transitions to secondary progressive MS. Currently available disease-modifying therapies（DMTs） for relapsing MS have been demonstrated to reduce disease activity, however most patients require a change in therapy over the course of their disease. Treatment goals include the prevention of relapses and disability accumulation and to achieve this objective requires careful planning. Sequencing of DMTs for individual patients should be designed in such a way to maximize disease control and minimize risk based on the mechanism of action, pharmacokinetic and pharmacodynamic properties of each therapy. This includes the DMT patients are being switched from to those they are being switched to. The reversibility of immune system effects should be a key consideration for DMT sequence selection. This feature varies across DMTs and should factor more prominently in decision making as newer treatments become available for the prevention of disability accumulation in patients with progressive MS. In this short review, we discuss the landscape of existing therapies with an eye to the future when planning for optimal DMT sequencing. While no cure exists for MS, efforts are being directed toward research in neuroregeneration with the hope for positive outcomes.展开更多
目的:探讨160 W绿激光汽化术(photoselective vaporization of prostate,PVP)治疗高危良性前列腺增生(benign prostatic hyperplasia,BPH)的疗效及安全性。方法:选取阜阳市第二人民医院泌尿外科收治的86例高危BPH患者,区组随机法分为经...目的:探讨160 W绿激光汽化术(photoselective vaporization of prostate,PVP)治疗高危良性前列腺增生(benign prostatic hyperplasia,BPH)的疗效及安全性。方法:选取阜阳市第二人民医院泌尿外科收治的86例高危BPH患者,区组随机法分为经尿道前列腺电切术(transurethral resection of prostate,TURP)组与160W PVP组,各43例。对两组围手术期指标、国际前列腺症状量表(International Prostate Symptom Scale,IPSS)评分、生活质量(quality of life score,QOL)评分和术后6个月随访情况进行比较。结果:160 W PVP组手术后血红蛋白(hemoglobin,Hb)下降值、术后导管留置时间和住院时间均少于TURP组,差异有统计学意义(P<0.05);随访结果显示:两组术后6个月IPSS、QOL评分均较术前明显下降,差异有统计学意义(P<0.05),两组间比较差异无统计学意义(P>0.05);160W PVP组总并发症发生率(6.98%)低于TURP组(23.26%),差异有统计学意义(P<0.05)。结论:160 W PVP是治疗高危BPH的有效术式,具有术中出血少、恢复快和并发症发生率低等优点,手术安全性更佳。展开更多
文摘Multiple sclerosis（MS） is characterized by chronic inflammation in conjunction with neurodegeneration within the central nervous system. Most individuals with MS begin with a relapsing remitting course that later transitions to secondary progressive MS. Currently available disease-modifying therapies（DMTs） for relapsing MS have been demonstrated to reduce disease activity, however most patients require a change in therapy over the course of their disease. Treatment goals include the prevention of relapses and disability accumulation and to achieve this objective requires careful planning. Sequencing of DMTs for individual patients should be designed in such a way to maximize disease control and minimize risk based on the mechanism of action, pharmacokinetic and pharmacodynamic properties of each therapy. This includes the DMT patients are being switched from to those they are being switched to. The reversibility of immune system effects should be a key consideration for DMT sequence selection. This feature varies across DMTs and should factor more prominently in decision making as newer treatments become available for the prevention of disability accumulation in patients with progressive MS. In this short review, we discuss the landscape of existing therapies with an eye to the future when planning for optimal DMT sequencing. While no cure exists for MS, efforts are being directed toward research in neuroregeneration with the hope for positive outcomes.
文摘目的:探讨160 W绿激光汽化术(photoselective vaporization of prostate,PVP)治疗高危良性前列腺增生(benign prostatic hyperplasia,BPH)的疗效及安全性。方法:选取阜阳市第二人民医院泌尿外科收治的86例高危BPH患者,区组随机法分为经尿道前列腺电切术(transurethral resection of prostate,TURP)组与160W PVP组,各43例。对两组围手术期指标、国际前列腺症状量表(International Prostate Symptom Scale,IPSS)评分、生活质量(quality of life score,QOL)评分和术后6个月随访情况进行比较。结果:160 W PVP组手术后血红蛋白(hemoglobin,Hb)下降值、术后导管留置时间和住院时间均少于TURP组,差异有统计学意义(P<0.05);随访结果显示:两组术后6个月IPSS、QOL评分均较术前明显下降,差异有统计学意义(P<0.05),两组间比较差异无统计学意义(P>0.05);160W PVP组总并发症发生率(6.98%)低于TURP组(23.26%),差异有统计学意义(P<0.05)。结论:160 W PVP是治疗高危BPH的有效术式,具有术中出血少、恢复快和并发症发生率低等优点,手术安全性更佳。
